Literature DB >> 22120473

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease.

Michael M Vickers1, Jair Bar, Ivan Gorn-Hondermann, Nirit Yarom, Manijeh Daneshmand, Jennifer E L Hanson, Christina L Addison, Timothy R Asmis, Derek J Jonker, Jean Maroun, Ian A J Lorimer, Glenwood D Goss, Jim Dimitroulakos.   

Abstract

MicroRNAs (miRs) are short non-coding RNAs that bind complementary sequences in mRNA resulting in translation repression and/or mRNA degradation. We investigated expression of the reported metastasis-associated miRs-335, 206, 135a, 146a, 146b, 10b, 21, let7a and let7b in normal mucosa, non-metastatic and metastatic colorectal cancer (CRC). Expression of target miRs in micro-dissected paraffin embedded tissues was evaluated in 15 primary tumours with adjacent normal tissue from patients that were disease-free at 4 years (cohort A) and 19 paired primary tumours with corresponding liver metastases (cohort B) by quantitative real-time PCR. Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC, while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases. In summary, we have shown stage-associated differential expression of five out of nine tested metastasis-associated miRs. We have further found that an analysis of these five miRs expression levels in primary tumors significantly correlates with the presence of metastatic disease, making this a potential clinically useful prognostic tool.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22120473     DOI: 10.1007/s10585-011-9435-3

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  40 in total

1.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

2.  Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer.

Authors:  Remco Nagel; Carlos le Sage; Begoña Diosdado; Maike van der Waal; Joachim A F Oude Vrielink; Anne Bolijn; Gerrit A Meijer; Reuven Agami
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

3.  Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases.

Authors:  Vlastimil Kulda; Martin Pesta; Ondrej Topolcan; Vaclav Liska; Vladislav Treska; Alan Sutnar; Karel Rupert; Marie Ludvikova; Vaclav Babuska; Lubos Holubec; Radim Cerny
Journal:  Cancer Genet Cytogenet       Date:  2010-07-15

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

7.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

8.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

9.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.

Authors:  Heidi J Peltier; Gary J Latham
Journal:  RNA       Date:  2008-03-28       Impact factor: 4.942

10.  Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer.

Authors:  O Slaby; M Svoboda; P Fabian; T Smerdova; D Knoflickova; M Bednarikova; R Nenutil; R Vyzula
Journal:  Oncology       Date:  2008-01-15       Impact factor: 2.935

View more
  53 in total

1.  Tumor microRNA-335 expression is associated with poor prognosis in human glioma.

Authors:  Jian Jiang; Xiaoyang Sun; Weijie Wang; Xiaodong Jin; Xiangfei Bo; Zhengming Li; Aimiao Bian; Ji Jiu; Xiaodong Wang; Dai Liu; Xiaobo Hui; Yanping Wang; Aifeng Wang; Lianshu Ding
Journal:  Med Oncol       Date:  2012-05-27       Impact factor: 3.064

Review 2.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  The fundamental role of miR-10b in metastatic cancer.

Authors:  Patrick Sheedy; Zdravka Medarova
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

4.  Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Authors:  J B Kjersem; T Ikdahl; O C Lingjaerde; T Guren; K M Tveit; E H Kure
Journal:  Mol Oncol       Date:  2013-09-21       Impact factor: 6.603

5.  Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer.

Authors:  Jie Yin; Zhigang Bai; Jianning Song; Yun Yang; Jin Wang; Wei Han; Jun Zhang; Hua Meng; Xuemei Ma; Yao Yang; Tingting Wang; Weirong Li; Zhongtao Zhang
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

Review 6.  MicroRNAs in colorectal cancer: role in metastasis and clinical perspectives.

Authors:  Shan Muhammad; Kavanjit Kaur; Rui Huang; Qian Zhang; Paviter Kaur; Hamza Obaid Yazdani; Muhammad Umar Bilal; Jiang Zheng; Liu Zheng; Xi-Shan Wang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer.

Authors:  Si-wei Xiong; Tian-xin Lin; Ke-wei Xu; Wen Dong; Xiao-hui Ling; Fu-neng Jiang; Guo Chen; Wei-de Zhong; Jian Huang
Journal:  Pathol Oncol Res       Date:  2013-03-03       Impact factor: 3.201

8.  The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer.

Authors:  Liselle C Bovell; Chandrakumar Shanmugam; Balananda-Dhurjati K Putcha; Venkat R Katkoori; Bin Zhang; Sejong Bae; Karan P Singh; William E Grizzle; Upender Manne
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

9.  MicroRNA-206 inhibits the viability and migration of human lung adenocarcinoma cells partly by targeting MET.

Authors:  Xi Chen; Zhong-Kai Tong; Jian-Ya Zhou; Ya-Ke Yao; Shu-Meng Zhang; Jian-Ying Zhou
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 10.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.